Sunitinib in Sarcomas of the Central Nervous System
Status:
Completed
Trial end date:
2021-04-02
Target enrollment:
Participant gender:
Summary
Background:
A sarcoma is a rare cancer. It grows in the body s connective tissue. Sarcomas in the brain
and central nervous system are especially rare. The drug Sunitinib has been approved in many
countries for treating other types of rare or advanced cancers. These include kidney,
pancreas, and bowel cancer. Researchers want to see if it can help people with sarcomas of
the central nervous system.
Objective:
To study the effects of Sunitinib on gliosarcomas or sarcomas of the central nervous system.
Eligibility:
Adults ages 18 and older with a gliosarcoma or sarcoma of the central nervous system
Design:
Participants will be screened with the following tests. Some may be done as part of their
regular cancer care:
Medical history
Medication review
Physical exam
Blood, heart, and pregnancy tests
Cranial scans to locate and measure their tumor
Participants will take Sunitinib by mouth every day for 2 weeks and then take none of the
drug for 1 week. These 3 weeks equal 1 cycle.
Participants will have 2 study visits in cycle 1. They will have 1 visit in all other cycles.
They will answer questions about quality of life and repeat some screening tests.
Participants will take their blood pressure at home weekly. They keep a diary of each dose of
Sunitinib and blood pressure reading.
Participants can choose to share data about their physical activity levels and quality of
sleep. These participants will wear a small, portable watch-sized accelerometer device on the
wrist for 6 cycles.
About 1 month after their last study drug dose, participants will have a final study visit.
They will have a physical exam, blood tests, and scans.